• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.

作者信息

Ammoun Sylwia, Evans D Gareth, Hilton David A, Streeter Adam, Hayward Christopher, Hanemann C Oliver

机构信息

Institute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.

Regional Genetic Service, St Mary's Hospital, Manchester, UK.

出版信息

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1184-1187. doi: 10.1136/jnnp-2018-319713. Epub 2019 Feb 4.

DOI:10.1136/jnnp-2018-319713
PMID:30718294
Abstract
摘要

相似文献

1
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.关于索拉非尼在2型神经纤维瘤病中的瘤内浓度和活性的0期试验。
J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1184-1187. doi: 10.1136/jnnp-2018-319713. Epub 2019 Feb 4.
2
Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion.索拉非尼诱导肾细胞癌细胞自噬性死亡是通过 Akt 抑制而不依赖于 ERK1/2 通路实现的。
PLoS One. 2018 Jul 26;13(7):e0200878. doi: 10.1371/journal.pone.0200878. eCollection 2018.
3
[Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].[PI3K和MEK的联合抑制对顺铂耐药卵巢癌细胞的增殖具有协同抑制作用]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Jun;30(6):592-6.
4
Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.地塞米松通过抑制细胞外信号调节激酶1/2通路和细胞周期蛋白D1的表达来抑制DU145细胞增殖和细胞周期。
Asian J Androl. 2008 Jul;10(4):635-41. doi: 10.1111/j.1745-7262.2008.00352.x. Epub 2007 Dec 20.
5
Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine.氨氯地平治疗的自发性高血压大鼠主动脉重塑过程中，Akt、半胱天冬酶和丝裂原活化蛋白激酶的差异调节是平滑肌细胞凋亡的基础。
Br J Pharmacol. 2007 Aug;151(8):1315-23. doi: 10.1038/sj.bjp.0707334. Epub 2007 Jun 25.
6
Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation.低浓度砷诱导细胞增殖过程中，CDC6 和细胞周期蛋白 D1 的蛋白稳定性依赖于 p38 MAPK/Akt/ERK1/2 信号通路的激活。
J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
7
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.剖析并靶向人类神经鞘瘤中依赖生长因子和不依赖生长因子的细胞外信号调节激酶通路
Cancer Res. 2008 Jul 1;68(13):5236-45. doi: 10.1158/0008-5472.CAN-07-5849.
8
Atorvastatin Calcium Inhibits PDGF-ββ-Induced Proliferation and Migration of VSMCs Through the G0/G1 Cell Cycle Arrest and Suppression of Activated PDGFRβ-PI3K-Akt Signaling Cascade.阿托伐他汀钙通过G0/G1期细胞周期阻滞和抑制活化的血小板衍生生长因子受体β-磷脂酰肌醇3-激酶-蛋白激酶B信号级联反应，抑制血小板衍生生长因子-ββ诱导的血管平滑肌细胞增殖和迁移。
Cell Physiol Biochem. 2017;44(1):215-228. doi: 10.1159/000484648. Epub 2017 Nov 9.
9
YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor.YC-1通过抑制细胞周期蛋白D1来抑制大鼠系膜细胞增殖，该抑制作用不依赖于cGMP途径，且可被p38丝裂原活化蛋白激酶抑制剂部分逆转。
Eur J Pharmacol. 2005 Jul 4;517(1-2):1-10. doi: 10.1016/j.ejphar.2005.04.046.
10
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.热休克蛋白90（HSP90）抑制剂17-AAG与阿霉素和U0126在间变性大细胞淋巴瘤中具有协同作用，与间变性淋巴瘤激酶（ALK）表达无关。
Exp Hematol. 2006 Dec;34(12):1670-9. doi: 10.1016/j.exphem.2006.07.002.

引用本文的文献

1
From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas.从实验台到病床边：向听神经瘤的治疗迈进。
Neurooncol Adv. 2024 Jun 24;6(1):vdae107. doi: 10.1093/noajnl/vdae107. eCollection 2024 Jan-Dec.
2
Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.神经纤维瘤病 2 型（NF2）相关前庭神经鞘瘤的靶向治疗进展。
Curr Oncol Rep. 2023 May;25(5):531-537. doi: 10.1007/s11912-023-01388-3. Epub 2023 Mar 18.
3
[Research progress on non-surgical treatment of vestibular schwannomas].
[前庭神经鞘瘤的非手术治疗研究进展]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Dec;36(12):971-976. doi: 10.13201/j.issn.2096-7993.2022.12.017.
4
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.组蛋白去乙酰化酶抑制剂AR-42用于2型神经纤维瘤病相关前庭神经鞘瘤和脑膜瘤的早期临床研究。
Laryngoscope Investig Otolaryngol. 2021 Aug 20;6(5):1008-1019. doi: 10.1002/lio2.643. eCollection 2021 Oct.